Merck & Company (6MK) Stock Forecast & Price Target

Compare

67 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

6MK Analyst Ratings

Moderate Buy

7 Buy

9 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

6MK Stock 12 Month Forecast

Average Price Target

€84.65

▲(21.97% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is €84.65 with a high forecast of €119.36 and a low forecast of €69.41. The average price target represents a 21.97% change from the last price of €69.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"€64","78":"€78","92":"€92","106":"€106","120":"€120"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":119.3550759,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€119.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.64899,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€84.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.4121718,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€69.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,78,92,106,120],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.309,75.00485199230769,78.70070398461539,82.39655597692308,86.09240796923076,89.78825996153846,93.48411195384615,97.17996394615385,100.87581593846154,104.57166793076922,108.26751992307692,111.96337191538461,115.65922390769231,{"y":119.3550759,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.309,72.33515307692308,73.36130615384616,74.38745923076922,75.4136123076923,76.43976538461538,77.46591846153846,78.49207153846153,79.51822461538461,80.54437769230769,81.57053076923077,82.59668384615384,83.62283692307692,{"y":84.64899,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.309,71.16309013846154,71.01718027692307,70.87127041538461,70.72536055384614,70.57945069230769,70.43354083076923,70.28763096923076,70.1417211076923,69.99581124615385,69.84990138461538,69.70399152307692,69.55808166153845,{"y":69.4121718,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103.461,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.331,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.23,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.773,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.739,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.933,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.059,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.348,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.111,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.229,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.446,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.309,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€119.36

Average Price Target€84.65

Lowest Price Target€69.41

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€84.65→€76.18

Hold

9.78%

Upside

Downgraded

09/17/25

Merck & Company (MRK) was downgraded to a Hold Rating at Roth MKM

Luisa Hector

Berenberg Bank

€84.65→€76.18

Hold

9.78%

Upside

Downgraded

09/16/25

Berenberg Bank downgrades Merck & Company (MRK) to a Hold

Chris Schott

J.P. Morgan

€101.58

Buy

46.37%

Upside

Reiterated

09/16/25

J.P. Morgan Keeps Their Buy Rating on Merck & Company (MRK)

Veda Pharmyne

TR | OpenAI - 4o

€81.26→€78.72

Buy

13.43%

Upside

Reiterated

09/13/25

AI Generated ArticleAI Generated Article

Daina Graybosch

Leerink Partners

―

Buy

―

Reiterated

09/09/25

Merck's Strategic Advantage in ADCs for ES-SCLC: A Buy Rating by Daina Graybosch

Asad Haider

Goldman Sachs

€79.57

Buy

14.65%

Upside

Reiterated

08/19/25

Merck & Co.'s Strategic Positioning and Market Potential Justify Buy Rating Despite Challenges

Courtney Breen

Bernstein

―

Hold

―

Reiterated

08/17/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Stoke Therapeutics (NASDAQ: STOK) and Regeneron (NASDAQ: REGN)

Evan Seigerman

BMO Capital

€69.41

Hold

0.02%

Upside

Reiterated

08/04/25

BMO Capital Sticks to Its Hold Rating for Merck & Company (MRK)

Mohit Bansal

Wells Fargo

€82.11→€76.18

Hold

9.78%

Upside

Reiterated

07/30/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)

Carter Gould

Cantor Fitzgerald

€70.26

Hold

1.24%

Upside

Reiterated

07/29/25

Cantor Fitzgerald Sticks to Its Hold Rating for Merck & Company (MRK)

Steve Scala

TD Cowen

€84.65

Hold

21.97%

Upside

Reiterated

07/28/25

Tim Anderson

Bank of America Securities

€83.8

Buy

20.75%

Upside

Reiterated

07/23/25

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)We reiterate our Buy rating and $99 PO on Merck (MRK).

Vamil Divan

Guggenheim

€91.42

Buy

31.73%

Upside

Reiterated

07/13/25

Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)

Trung Huynh

UBS

€88.88

Buy

28.07%

Upside

Reiterated

07/10/25

UBS Sticks to Their Buy Rating for Merck & Company (MRK)

Tycho Peterson

Jefferies

€116.82→€119.36

Buy

71.98%

Upside

Reiterated

07/10/25

Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€84.65→€76.18

Hold

9.78%

Upside

Downgraded

09/17/25

Merck & Company (MRK) was downgraded to a Hold Rating at Roth MKM

Luisa Hector

Berenberg Bank

€84.65→€76.18

Hold

9.78%

Upside

Downgraded

09/16/25

Berenberg Bank downgrades Merck & Company (MRK) to a Hold

Chris Schott

J.P. Morgan

€101.58

Buy

46.37%

Upside

Reiterated

09/16/25

J.P. Morgan Keeps Their Buy Rating on Merck & Company (MRK)

Veda Pharmyne

TR | OpenAI - 4o

€81.26→€78.72

Buy

13.43%

Upside

Reiterated

09/13/25

AI Generated ArticleAI Generated Article

Daina Graybosch

Leerink Partners

―

Buy

―

Reiterated

09/09/25

Merck's Strategic Advantage in ADCs for ES-SCLC: A Buy Rating by Daina Graybosch

Asad Haider

Goldman Sachs

€79.57

Buy

14.65%

Upside

Reiterated

08/19/25

Merck & Co.'s Strategic Positioning and Market Potential Justify Buy Rating Despite Challenges

Courtney Breen

Bernstein

―

Hold

―

Reiterated

08/17/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Stoke Therapeutics (NASDAQ: STOK) and Regeneron (NASDAQ: REGN)

Evan Seigerman

BMO Capital

€69.41

Hold

0.02%

Upside

Reiterated

08/04/25

BMO Capital Sticks to Its Hold Rating for Merck & Company (MRK)

Mohit Bansal

Wells Fargo

€82.11→€76.18

Hold

9.78%

Upside

Reiterated

07/30/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)

Carter Gould

Cantor Fitzgerald

€70.26

Hold

1.24%

Upside

Reiterated

07/29/25

Cantor Fitzgerald Sticks to Its Hold Rating for Merck & Company (MRK)

Steve Scala

TD Cowen

€84.65

Hold

21.97%

Upside

Reiterated

07/28/25

Tim Anderson

Bank of America Securities

€83.8

Buy

20.75%

Upside

Reiterated

07/23/25

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)We reiterate our Buy rating and $99 PO on Merck (MRK).

Vamil Divan

Guggenheim

€91.42

Buy

31.73%

Upside

Reiterated

07/13/25

Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)

Trung Huynh

UBS

€88.88

Buy

28.07%

Upside

Reiterated

07/10/25

UBS Sticks to Their Buy Rating for Merck & Company (MRK)

Tycho Peterson

Jefferies

€116.82→€119.36

Buy

71.98%

Upside

Reiterated

07/10/25

Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

1 Month

xxx

Success Rate

10/14 ratings generated profit

Average Return

+1.53%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.53% per trade.

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+2.76%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +2.76% per trade.

1 Year

Tim AndersonBank of America Securities

Success Rate

8/14 ratings generated profit

Average Return

+3.00%

reiterated a buy rating 2 months ago

Copying Tim Anderson's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +3.00% per trade.

2 Years

xxx

Success Rate

15/18 ratings generated profit

Average Return

+12.19%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +12.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6MK Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 6MK has received 25 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. 6MK average Analyst price target in the past 3 months is 84.65.

Each month's total comprises the sum of three months' worth of ratings.

6MK Financial Forecast

6MK Earnings Forecast

Next quarter’s earnings estimate for 6MK is €2.02 with a range of €1.98 to €2.09. The previous quarter’s EPS was €1.81. 6MK beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.33% of the time in the same period. In the last calendar year 6MK has Outperformed its overall industry.

6MK Sales Forecast

Next quarter’s sales forecast for 6MK is €14.49B with a range of €14.14B to €14.79B. The previous quarter’s sales results were €13.45B. 6MK beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 44.14% of the time in the same period. In the last calendar year 6MK has Outperformed its overall industry.

6MK Stock Forecast FAQ

What is DE:6MK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 84.65.

What is DE:6MK’s upside potential, based on the analysts’ average price target?

Merck & Company has 21.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Merck & Company a Buy, Sell or Hold?

Merck & Company has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 9 hold ratings and 0 sell ratings.

What is Merck & Company’s share price target?

The average share price target for Merck & Company is 84.65. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €119.36 ,and the lowest forecast is €69.41. The average share price target represents 21.97% Increase from the current price of €69.4.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Merck & Company?

To buy shares of DE:6MK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Merck & Company (6MK) Stock Forecast & Price Target

6MK Analyst Ratings

6MK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

6MK Analyst Recommendation Trends

6MK Financial Forecast

6MK Earnings Forecast

6MK Sales Forecast

6MK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts